Reuters logo
3 个月前
BRIEF-Minerva Neurosciences announces outcome of meeting with FDA
2017年5月15日 / 中午12点25分 / 3 个月前

BRIEF-Minerva Neurosciences announces outcome of meeting with FDA

May 15 (Reuters) - Minerva Neurosciences Inc

* Minerva announces outcome of end-of-phase 2 meeting with FDA

* Minerva - pivotal phase 3 trial design to include monotherapy administration of MIN-101, primary endpoint of improvement in negative symptoms of schizophrenia

* Minerva Neurosciences Inc - planned initiation of MIN-101 phase 3 development in second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below